PMID- 18362304
OWN - NLM
STAT- MEDLINE
DCOM- 20080409
LR  - 20220317
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
VI  - 158
IP  - 4
DP  - 2008 Apr
TI  - Risk factors for post-treatment hypogonadism in testicular cancer patients.
PG  - 561-70
LID - 10.1530/EJE-07-0684 [doi]
AB  - OBJECTIVES: Testicular germ-cell cancer (TGCC) patients are at risk of developing 
      hypogonadism but no risk factors have yet been defined. METHODS: Blood was 
      collected from 143 TGCC patients (after orchidectomy, prior to further therapy 
      (T0) and 6, 12, 24, 36 and 60 months (T6, T12, T24, T36 and T60) after therapy). 
      Biological hypogonadism (BH) was defined as: serum testosterone below 10 nmol/l 
      and/or LH >10 IU/l; odds ratios (ORs) for BH with BH at T0, age, stage of 
      disease, testicular characteristics, and androgen receptor polymorphism as 
      predictors were calculated as well as the OR for developing BH post-treatment 
      (one to two cycles of adjuvant chemotherapy (ACT) versus three to four cycles of 
      higher dose chemotherapy (HCT) versus adjuvant radiotherapy (RT)). RESULTS: HCT 
      increased the OR for BH at T6 (OR 22, 95% confidence interval (CI) 4.4-118) and 
      T12 (OR 5.8, 95% CI 1.5-22). RT increased the OR at T6 (OR 10, 95% CI 2.1-47) and 
      at T12 (OR 3.9, 95% CI 1.1-14). Microlithiasis predicted BH at T0 (OR 11, 95% CI 
      1.2-112), T12 (OR 3.9, 95% CI 1.1-13), T24 (OR 3.0, 95% CI 1.0-8.8), T36 (OR 5.4, 
      95% CI 1.7-17) and T60 (OR 4.4, 95% CI 1.2-16). BH at T0 was a risk for BH at T6 
      (OR 53, 95% CI 19-145), T12 (OR 125, 95% CI 37-430), T24 (OR 88, 95% CI 26-300) 
      and T36 (OR 121, 95% CI 32-460). CONCLUSIONS: It is clinically relevant that BH 
      at T0 and testicular microlithiasis were predictive factors for post-treatment 
      BH. HCT and RT gave temporary BH.
FAU - Eberhard, Jakob
AU  - Eberhard J
AD  - Department of Oncology, Lund University Hospital, Lund University, SE 22185 Lund, 
      Sweden. jakob.eberhard@med.lu.se
FAU - Stahl, Olof
AU  - Stahl O
FAU - Cwikiel, Magdalena
AU  - Cwikiel M
FAU - Cavallin-Stahl, Eva
AU  - Cavallin-Stahl E
FAU - Giwercman, Yvonne
AU  - Giwercman Y
FAU - Salmonson, Eva Cecilia
AU  - Salmonson EC
FAU - Giwercman, Aleksander
AU  - Giwercman A
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology
JID - 9423848
RN  - 04079A1RDZ (Cytarabine)
RN  - 3XMK78S47O (Testosterone)
RN  - 80168379AG (Doxorubicin)
RN  - FTK8U1GZNX (Thioguanine)
RN  - ACT protocol
SB  - IM
MH  - Adult
MH  - Algorithms
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Chemotherapy, Adjuvant/adverse effects
MH  - Combined Modality Therapy/adverse effects
MH  - Cytarabine/adverse effects/therapeutic use
MH  - Doxorubicin/adverse effects/therapeutic use
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypogonadism/blood/*etiology
MH  - Lithiasis/complications
MH  - Longitudinal Studies
MH  - Male
MH  - Neoplasms, Germ Cell and Embryonal/blood/*surgery
MH  - Orchiectomy/adverse effects
MH  - Prospective Studies
MH  - Radiation Injuries/complications
MH  - Radiotherapy/adverse effects
MH  - Radiotherapy, Adjuvant/adverse effects
MH  - Risk Factors
MH  - Testicular Diseases/complications
MH  - Testicular Neoplasms/blood/*therapy
MH  - Testosterone/blood
MH  - Thioguanine/adverse effects/therapeutic use
EDAT- 2008/03/26 09:00
MHDA- 2008/04/10 09:00
CRDT- 2008/03/26 09:00
PHST- 2008/03/26 09:00 [pubmed]
PHST- 2008/04/10 09:00 [medline]
PHST- 2008/03/26 09:00 [entrez]
AID - EJE-07-0684 [pii]
AID - 10.1530/EJE-07-0684 [doi]
PST - ppublish
SO  - Eur J Endocrinol. 2008 Apr;158(4):561-70. doi: 10.1530/EJE-07-0684.